Clinical trials · Florida
Macular Degeneration clinical trials in Florida
We’re tracking 32 recruiting macular degeneration studies with a site in Florida — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Florida
- NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Altamonte Springs, FloridaAges 50 years+ - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Fort Myers, FloridaAges 50 years+ - NCT03178149RecruitingPhase 1
Study of a new eye treatment for dry macular degeneration
This Phase 1 trial tests the safety and side effects of ASP7317 in older adults whose central vision is worsening from dry age-related macular degeneration (geographic atrophy). If you qualify, you would receive treatment in the study eye and be closely monitored for about a year.
Pensacola, FloridaAges 50 years+ - NCT06635148RecruitingPhase 2
Long-term study for geographic atrophy treatment
This study is for people who already took part in a previous trial for geographic atrophy (a late stage of dry age-related macular degeneration) and received the study drug or a sham. It looks at the long-term safety of the treatment over time.
Gainesville, FloridaAges 60 years+ - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Tampa, FloridaAges 50 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Miami, FloridaAges 50 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Deerfield Beach, FloridaAges 50 years+ - NCT06132035RecruitingPhase 1
CG-P5 eye drops for wet macular degeneration
This study tests a new eye drop (CG-P5) for people with wet age-related macular degeneration. It aims to see if the drops are safe and may help improve vision.
Deerfield Beach, FloridaAges 50 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Deerfield Beach, FloridaAges 50 years+ - NCT05986864RecruitingPhase 1/Phase 2
Gene therapy injection for wet AMD
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
St. Petersburg, FloridaAges 50 years+ - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Deerfield Beach, FloridaAges 50 years+ - NCT05197270RecruitingPhase 1/Phase 2
Study drug 4D-150 for wet macular degeneration not responding enough
This early-stage study tests 4D-150 (a one-time injection into the eye) for “wet” age-related macular degeneration to see if it can better control leaking blood vessel growth and reduce fluid. It’s for people who are already getting anti-VEGF injections but still need ongoing treatment because of signs of fluid on special eye scans.
Deerfield Beach, FloridaAges 50 years+ - NCT07441642RecruitingPhase 2
Testing FWY003 eye drops for geographic atrophy (dry AMD)
This trial tests a new eye drop called FWY003 against a placebo (an inactive drop) to see if it can slow the progression of geographic atrophy (the dry form of age-related macular degeneration). It may help people who have moderate vision loss from this condition.
Boynton Beach, FloridaAges 50 years+ - NCT05481827Enrolling by invitationPhase 2
Safety follow-up for GT005 in geographic eye damage
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
Gainesville, FloridaAges 55 years+ - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Pensacola, FloridaAges 50 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Fort Lauderdale, FloridaAges 50 years+ - NCT07680244Recruiting
Testing a new tool to see retina in eye scans
This trial is testing a new software tool that helps doctors see and assess different parts of the retina in eye scans. It aims to see how well the tool works in people with and without certain retina conditions.
Fort Lauderdale, FloridaAges 18 years+ - NCT03011541Recruiting
Stem cell treatment for damaged retina or optic nerve
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
Coral Springs, FloridaAges 18 years+ - NCT06942572RecruitingPhase 1/Phase 2
Gene therapy trial for Stargardt disease
This trial tests a new gene therapy called SB-007 for people with Stargardt disease (STGD1). It is given as an injection under the retina to see if it is safe and can help slow vision loss.
Miami, FloridaAges 12–65 - NCT02402660Enrolling by invitationPhase 2
Test ALK-001 for Stargardt disease eye changes and comfort
This Phase 2 study tests how well ALK-001 is tolerated and whether it can slow or improve vision-related changes in people with Stargardt disease. It mainly looks at safety (tolerability) and signs in the eye over about 24 months.
Gainesville, FloridaAges 8–70 - NCT07205887RecruitingPhase 2
Study of EYE103 for wet AMD or macular edema after BRVO
This trial tests an investigational drug called EYE103 injected into the eye to treat two conditions: wet age-related macular degeneration (AMD) or macular edema following a branch retinal vein occlusion (BRVO). It looks at how safe and effective the drug is for people who have not had treatment before or have not responded well to previous treatments.
Fort Lauderdale, FloridaAges 18 years+ - NCT07215390RecruitingPhase 2
Study of APL-3007 plus Syfovre for geographic atrophy
This trial tests whether a new drug called APL-3007, when added to your current Syfovre treatment, can slow the progression of geographic atrophy (an advanced form of dry age-related macular degeneration). It's for people who have already been on Syfovre for at least 6 months.
Orlando, FloridaAges 60 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Bonita Springs, FloridaAges 50–85 - NCT03683251RecruitingPhase 3
Extension study for a refillable eye implant plus ranibizumab
This trial studies whether continuing treatment with a refillable eye implant (Port Delivery System) and ranibizumab injection helps control a specific type of wet macular degeneration. It’s mainly for people who already finished an earlier related study and are able to keep up with frequent eye checks and procedures.
Boynton Beach, FloridaAges 50 years+
Macular Degeneration trials by city in Florida
Where these studies are running in Florida
Institutions with a site for the recruiting macular degeneration studies listed above.
- Retina Vitreous Associates of Florida · 11 studies
- Retina Group of Florida · 7 studies
- Retina Specialty Institute · 7 studies
- Florida Retina Institute · 5 studies
- Center for Retina and Macular Disease · 4 studies
- Vitreo Retinal Associates · 4 studies
- Fort Lauderdale Eye Institute · 3 studies
- National Ophthalmic Research Institute · 3 studies
What taking part in a macular degeneration study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Macular Degeneration trials in other states
Common questions
- Are there macular degeneration clinical trials in Florida?
- Yes. We're currently tracking 32 recruiting macular degeneration studies with a site in Florida, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a macular degeneration study in Florida?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Florida to take part?
- Not necessarily. These studies have a site in Florida, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a macular degeneration trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New macular degeneration studies open in Florida regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.